Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Feb. 3, 2025—The Food and Drug Administration approved a label expansion for the Roche Pathway anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody to identify patients with hormone-receptor-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with Enhertu.
The CDx Digital Education Portal, your gateway to centralized and comprehensive companion diagnostic (CDx) learning from Agilent. Find everything you need to master your command of Agilent CDx assays and biomarker interpretation, all in one place. Learn More.
Jan. 31, 2025—Genomadix announced it has received a medical device license from Health Canada permitting marketing of its Genomadix Cube CYP2C19 system, an automated sample-to-result PCR test.
Webinar presenters Marilyn M. Bui, MD, PhD, FCAP, Professor of Pathology and Scientific Director of Analytic Microscopy Core, Moffitt Cancer Center, and Savitri Krishnamurthy, MD, Professor, Department of Pathology, The University of Texas MD Anderson Cancer Center, and Patricia M. Raciti, MD, Scientific Director, Early Clinical Development and Translational Research, J&J Innovative Medicine, and Sylvia L. Asa, MD, PhD, Consultant in Endocrine Pathology, University Hospitals Cleveland Medical Center, Professor of Pathology, Case Western Reserve University discuss evaluation and implementation of AI tools for clinical use.
Webinar presenters Pranil K. Chandra, DO, Senior Vice President, Chief Genomics Officer PathGroup, and Nayan J. Sarma, PhD, HCLD/CC (ABB), Associate Director of Molecular Oncology PathGroup, and Jeff Gregg, MD, Vice President Medical Affairs, Biofidelity, Professor of Pathology and Laboratory Medicine, University of Nevada School of Medicine, address the gaps and limitations of CGP by using innovative simplified genomic profiling solutions that work for challenging samples not analyzable by CGP.
Jan. 30, 2025—Roche announced that the Tina-quant Lipoprotein (a) Gen.2 Molarity assay has received 510(k) clearance from the FDA.
Jan. 28, 2025—Beckman Coulter Diagnostics announced the FDA has granted breakthrough device designation to the Access p‑Tau217/β-Amyloid 1-42 plasma ratio.
Jan. 22, 2025—Roche announced that the FDA has granted 510(k) clearance and CLIA waiver for its Cobas Liat sexually transmitted infection multiplex assay panels.
Jan. 21, 2025—Inflammatix announced that the FDA has granted marketing authorization for the TriVerity test system, a molecular test for patients with suspected acute infection or sepsis.
Jan. 17, 2025—Mayo Clinic announced the formation of Mayo Clinic Digital Pathology, designed on a platform architecture “to unlock the power of its archive of digital slides to revolutionize pathology and accelerate medical breakthroughs,” the organization said in its Jan. 13 press release.
